Catabasis Pharmaceuticals, Inc. Names Andrew Nichols, Ph.D., Vice President Of Research

CAMBRIDGE, Mass., Feb. 26, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced that it has named Andrew Nichols, Ph.D., to the newly-created position of vice president of research. Dr. Nichols brings to Catabasis 25 years of drug development experience, leading efforts from target discovery through translational research and early clinical development for pharmaceutical and biotechnology companies.

"We are thrilled to add Andy Nichols to the Catabasis team," said Michael Jirousek, Ph.D., co-founder and chief scientific officer of Catabasis. "Andy brings valuable drug development experience, particularly in lipid and inflammatory disorders. We look forward to leveraging Andy's capabilities as we progress our CAT-2003 and CAT-1004 programs through Phase 2 development and advance additional programs into the clinic."

Prior to joining Catabasis, Dr. Nichols was associate vice president, cardiometabolic diseases at Merck Research Laboratories, leading drug discovery and early clinical development programs. Prior to Merck, Dr. Nichols was vice president of preclinical research at Zafgen Inc., vice president of research at Alinea Pharmaceuticals Inc., vice president of drug discovery project leadership at Millennium Pharmaceuticals Inc. and director of the Alliance Management Group at SmithKline Beecham Corp. He has worked across multiple therapeutic areas, including cardiovascular, metabolic, oncology and inflammation. He holds his B.Sc. in Pharmacology from the University of Leeds, England, and his M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England.

About Catabasis

Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled an experienced team that is passionately committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit for more information.

Corporate Contact
Amy Lynch
Catabasis Pharmaceuticals Inc.
T: (617)-349-1971
[email protected]

Media Contacts
Tony Russo, Ph.D.
Matt Middleman, M.D.
T: 212-845-4251
T: 212-845-4272
[email protected]
[email protected]

SOURCE Catabasis Pharmaceuticals Inc.